Fang B - Search Results

1

Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer.

Fang B, Eisensmith RC, Li XH, Finegold MJ, Shedlovsky A, Dove W, Woo SL. Fang B, et al. Gene Ther. 1994 Jul;1(4):247-54. Gene Ther. 1994. PMID: 7584088

2

Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression.

Fang B, Eisensmith RC, Wang H, Kay MA, Cross RE, Landen CN, Gordon G, Bellinger DA, Read MS, Hu PC, et al. Fang B, et al. Hum Gene Ther. 1995 Aug;6(8):1039-44. doi: 10.1089/hum.1995.6.8-1039. Hum Gene Ther. 1995. PMID: 7578416

3

In vivo gene therapy for hyperlipidemia: phenotypic correction in Watanabe rabbits by hepatic delivery of the rabbit LDL receptor gene.

Li J, Fang B, Eisensmith RC, Li XH, Nasonkin I, Lin-Lee YC, Mims MP, Hughes A, Montgomery CD, Roberts JD, et al. Li J, et al. Among authors: fang b. J Clin Invest. 1995 Feb;95(2):768-73. doi: 10.1172/JCI117725. J Clin Invest. 1995. PMID: 7860759 Free PMC article.

4

In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.

Kay MA, Landen CN, Rothenberg SR, Taylor LA, Leland F, Wiehle S, Fang B, Bellinger D, Finegold M, Thompson AR, et al. Kay MA, et al. Among authors: fang b. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2353-7. doi: 10.1073/pnas.91.6.2353. Proc Natl Acad Sci U S A. 1994. PMID: 8134398 Free PMC article.

5

Lack of persistence of E1- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs.

Fang B, Wang H, Gordon G, Bellinger DA, Read MS, Brinkhous KM, Woo SL, Eisensmith RC. Fang B, et al. Gene Ther. 1996 Mar;3(3):217-22. Gene Ther. 1996. PMID: 8646552

6

Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide.

Bouvet M, Fang B, Ekmekcioglu S, Ji L, Bucana CD, Hamada K, Grimm EA, Roth JA. Bouvet M, et al. Among authors: fang b. Gene Ther. 1998 Feb;5(2):189-95. doi: 10.1038/sj.gt.3300564. Gene Ther. 1998. PMID: 9578838

7

Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer.

Bouvet M, Ellis LM, Nishizaki M, Fujiwara T, Liu W, Bucana CD, Fang B, Lee JJ, Roth JA. Bouvet M, et al. Among authors: fang b. Cancer Res. 1998 Jun 1;58(11):2288-92. Cancer Res. 1998. PMID: 9622060

8

Intercellular trafficking of VP22-GFP fusion proteins is not observed in cultured mammalian cells.

Fang B, Xu B, Koch P, Roth JA. Fang B, et al. Gene Ther. 1998 Oct;5(10):1420-4. doi: 10.1038/sj.gt.3300741. Gene Ther. 1998. PMID: 9930348

9

Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.

Ji L, Bouvet M, Price RE, Roth JA, Fang B. Ji L, et al. Among authors: fang b. Gene Ther. 1999 Mar;6(3):393-402. doi: 10.1038/sj.gt.3300825. Gene Ther. 1999. PMID: 10435089

10

Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines.

Pearson AS, Koch PE, Atkinson N, Xiong M, Finberg RW, Roth JA, Fang B. Pearson AS, et al. Among authors: fang b. Clin Cancer Res. 1999 Dec;5(12):4208-13. Clin Cancer Res. 1999. PMID: 10632362

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,496 results

Search Page

Filters